Latest news and insights on the pharmaceutical industry | Indian Pharma Post
Clinical Trials
Clinical Trials | 01 January 2026

Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials

The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates

Clinical Trials
Clinical Trials | 01 January 2026

SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent

The study will run across 18 sites and enroll roughly 200 patients over 24 months

Clinical Trials
Clinical Trials | 31 December 2025

GenSight Biologics gets early access nod for candidate gene therapy in Israel

Applications include detailed scientific rationale and supporting clinical evidence

Clinical Trials
Clinical Trials | 31 December 2025

CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers

The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively

Clinical Trials
Clinical Trials | 31 December 2025

Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance

The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026

Clinical Trials
Clinical Trials | 30 December 2025

One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty

The study met its primary endpoint with flying colors

Clinical Trials
Clinical Trials | 30 December 2025

Biohaven reports Phase 2 depression trial results

Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials

Clinical Trials
Clinical Trials | 30 December 2025

Edgewise Therapeutics reports positive updates from HCM drug EDG-7500

CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM

Clinical Trials
Clinical Trials | 30 December 2025

Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours

CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development

Clinical Trials
Clinical Trials | 29 December 2025

Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial

Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis

Clinical Trials
Clinical Trials | 29 December 2025

SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer

The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38

Clinical Trials
Clinical Trials | 27 December 2025

InnoCare Pharma gets green light for Phase II trial of oral lupus drug

CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions

Clinical Trials
Clinical Trials | 27 December 2025

IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy

The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain

Clinical Trials
Clinical Trials | 25 December 2025

Lunit SCOPE matches pathologist accuracy in HER2 scoring for advanced biliary tract cancer

Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology

Clinical Trials
Clinical Trials | 24 December 2025

Gilead licenses Assembly Bio's investigational Herpes drugs after positive phase 1b data

Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option

Clinical Trials
Clinical Trials | 24 December 2025

Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial

Adverse events were consistent with valbenazine’s established safety profile

Clinical Trials
Clinical Trials | 23 December 2025

LATIFY Phase III trial of Ceralasertib fails to improve survival in advanced lung cancer

The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy

Clinical Trials
Clinical Trials | 23 December 2025

Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug

The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa

Clinical Trials
Clinical Trials | 22 December 2025

Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial

The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile

Clinical Trials
Clinical Trials | 22 December 2025

Ipsen’s FALKON trial falls short in rare FOP study, offers key insights

FOP is a rare genetic disorder caused by mutations in the ALK2 kinase

Startup

Digitization